Promore Pharma
25.10.2021 09:21:54 CEST | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / October 25, 2021 / Promore Pharma (STO:PROMO) (FRA:8T0)
Stockholm 25 October 2021 - Promore Pharma AB, a Swedish biopharmaceutical company that develops peptide-based drug candidates, announces that a peer-reviewed scientific article describing the results of a clinical study with ropocamptide for the treatment of venous leg ulcers has been published in the journal Wound Repair and Regeneration.
In 2020, Promore Pharma completed a clinical trial, HEAL LL-37, a phase IIb double-blind, randomized, placebo-controlled study aimed at evaluating the efficacy and safety of a new drug, LL-37 / ropocamptide for local administration in combination with compression therapy. The study was performed on 148 patients suffering from difficult-to-heal venous leg ulcers.
Today, the company announces that a scientific article has been published in the journal Wound Repair and Regeneration, which is the journal of the international society in wound care, Wound Healing Society. Co-authors of the article are several internationally renowned subject area experts, including professors Jan Apelqvist, Arkadiusz Jawien, and Folke Sjöberg.
" We are very content that the results of HEAL LL-37 are now published and available to the scientific community and the general public. The publication is a confirmation of the quality of the completed clinical study ", says Jonas Ekblom, CEO of Promore Pharma.
" Once again, we thank all the staff at the healthcare facilities who have participated in the study for their valuable contributions, " says Margit Mahlapuu, CSO of Promore Pharma.
The published article is entitled "Evaluation of LL-37 in Healing of Hard-to-Heal Venous Leg Ulcers: a Multicentric Prospective Randomized Placebo-Controlled Clinical Trial" and can be read in its entirety via the following link:
https://onlinelibrary.wiley.com/doi/full/10.1111/wrr.12977
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com
Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.
Attachments
SOURCE: Promore Pharma
View source version on accesswire.com:
https://www.accesswire.com/669452/Promore-Pharma-Announces-that-Scientific-Article-has-Been-Published-on-Clinical-Study-Results-with-Ropocamptide-for-Venous-Leg-Ulcers
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Fermi Names Lee McIntire as Chief Executive Officer12.8.2026 22:01:00 CEST | Press release
Engineering executive with more than 40 years of experience building and operating complex global industrial and governmental projects at Bechtel, CH2M Hill, and TerraPower DALLAS, TX / ACCESS Newswire / August 12, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), today named Lee McIntire Chief Executive Officer, effective Tuesday, August 11, 2026. McIntire has served as an independent director on Fermi's Board since September 2025. "Fermi's next chapter is a construction and power delivery story, and we believe Lee is the ideal executive to lead Fermi through that process," said Marius Haas, Chairman of the Board of Fermi Inc. "The job now is to build on schedule, on budget, and safely. Lee has spent 40 years delivering exactly this kind of large, complex project. He also knows Fermi from the inside, having served on our board through our latest period of growth, and he brings a reputation for integrity that Fermi's customers, employees
Model ML Secures Investment From HSBC Asset Management to Scale Its Agentic Operating System for Financial Services12.8.2026 18:05:00 CEST | Press release
The investment reflects growing demand for specialist AI platforms designed specifically for financial services. LONDON, UK / ACCESS Newswire / August 12, 2026 / Model ML has announced an investment from HSBC Asset Management, made through its flagship Venture Capital (VC) strategy. The funding will support Model ML's growth as the focus of enterprise AI shifts from individual models to the systems required to implement them. Model ML's platform is purpose-built for financial services. The company works with many of the world's leading banks, asset managers and advisory firms, helping to automate complex workflows across research, due diligence, financial analysis and client-ready document creation, while maintaining governance, accuracy and consistency. Its model-agnostic approach routes each task to the AI model best suited to the job, enabling firms to benefit from advances across the AI ecosystem without changing the way teams work. The company has grown rapidly since launching les
GoodData.AI Cuts BI Migration From 18 Months to Weeks for DACH Enterprises, Opening the Fastest Route to Production AI12.8.2026 16:20:00 CEST | Press release
With around 80 percent of migration functions automated, enterprises skip the multi-year consulting engagement that has kept them on aging BI platforms. SAN FRANCISCO, CA / ACCESS Newswire / August 12, 2026 / GoodData.AI today announced its AI-driven BI migration offering for enterprises across Germany, Austria, and Switzerland, delivered with German-language support and a regional team. Migration agents are able to move organizations off Tableau, Power BI, Qlik, Looker, MicroStrategy, and any other BI platform in days to weeks instead of the 12 to 18 months that a manual rebuild takes. Up to 80 percent of the migration work is automated, which cuts the cost along with the timeline, and GoodData engineers review every change before the customer approves it. It follows GoodData.AI's expansion in the region earlier this year and its work with DATEV, one of Germany's most recognized enterprise software companies. "Every migration conversation in Germany starts with the same question: will
Karbon-X and Core Energy Sign Letter of Intent to Explore Commercial EV Charging Infrastructure in South America12.8.2026 15:00:00 CEST | Press release
Collaboration provides Karbon-X with an opportunity to apply its project development and carbon market capabilities to commercial transportation infrastructure in the Southern Cone. CALGARY, AB / ACCESS Newswire / August 12, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has signed a non-binding Letter of Intent ("LOI") with Core Energy ("Core Energy"), to explore a potential commercial electric vehicle ("EV") fast-charging infrastructure project in South America. The proposed collaboration is intended to bring together Core Energy's local project development capabilities and Karbon-X's experience evaluating and developing climate projects and carbon market opportunities. During the initial exploratory phase, the companies expect to jointly assess the project's preliminary technical and commercial considerations and prepare a Concept Note outlining the proposed infrastructure model and its pot
Fermi and Hillcore Energy Capital Announce 2.6 Gigawatt Power Strategic Alliance for Project Matador11.8.2026 23:15:00 CEST | Press release
Doubles Fermi power to market to 4.8 gigawatts (GW) over the next ~30 months Build-Own-Operate-Transfer structure accelerates one of America's largest AI campus power programs - with no capital outlay by Fermi DALLAS, TX / ACCESS Newswire / August 11, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), announced the execution of a framework agreement with Hillcore Energy Capital Corporation ("Hillcore") under which Hillcore will finance, build, own and operate the Hillcore Power Center, an approximately 2.6 GW power complex at Fermi's Project Matador campus in Carson County, Texas, under a Build-Own-Operate-Transfer (BOOT) structure. The Hillcore Power Center will comprise approximately 2.5 GW of natural gas-fired generation, developed in phases, together with approximately 100 megawatts (MW) of solar generation and battery energy storage. Construction of the first power block, approximately 350 MW, will begin on execution of definitive ag
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom